Cancer (Oncology)
Cancer (Oncology)
Fulviglen 250® Fulvestrant Injection
Fulvestrant 250mg
- Composition
- Fulvestrant 250mg
- Dosage form
- Injection
- Pack size
- Prefilled Synringe of 5ml Injection
- Manufacturer
- Glenmark Pharmaceuticals
- Also known as
- Faslodex
Supplied against a valid prescription where required, in line with the regulations of the destination country.
Fulviglen 250 mg contains fulvestrant, an anti-oestrogen medicine used to treat certain types of advanced or metastatic breast cancer in postmenopausal women. It blocks oestrogen receptors and reduces their availability on cancer cells, limiting hormone-driven tumour growth
As prescribed by a doctor. Dose and duration depend on the condition being treated and the patient. Do not change the dose without medical advice.
Side effects vary by patient. Common and serious side effects are listed in the pack insert. Contact a doctor if you have severe or unexpected symptoms.
Tell your doctor about other medicines you take, allergies, pregnancy or breastfeeding, and any liver or kidney conditions before use.
Store below 30 °C in a dry place, in the original pack, out of reach of children.
Need product documents?
Ask for the pack insert, batch details or a COA with your quote.
Ask on WhatsApp →Licensed wholesalerForm 20B & 21B, Delhi
Discreet packagingPlain outer box, no product labels
Worldwide shippingDirect to you or your customer